Project Grant R01CA316649
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $448K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $642,242 under the Cancer Biology Research program (CFDA 93.396) on May 15, 2026, with completion targeted for April 30, 2031. The funded research project investigates the function and therapeutic implications of Neuregulin 3 (NRG3) in breast cancer brain metastasis, addressing a critical gap in understanding how luminal breast cancer cells transition...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $501,422 Project Grant to Columbia University's Health Sciences Division, effective May 1, 2026 through April 30, 2031, under the Cancer Biology Research program (CFDA 93.396). The award funds fundamental research to identify and validate novel synthetic lethal (SL) targets for cancer treatment, specifically exploiting ribosomal stress in two molecularly distinct cancer subtypes: biallelic chromosome 9p21.3-deleted...
- Federal Project Grant Award Summary New York University School of Medicine received a $585,482 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award funds fundamental investigation into the molecular mechanisms of breast cancer metastasis, specifically examining the role of the translation initiation factor DAP5 (Death-Associated Protein 5) in selective...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University a Project Grant of $702,132 under the Cancer Treatment Research program (CFDA 93.395) to conduct multiplex single-cell chemical genomics research focused on identifying small molecule modulators of glioblastoma immunogenicity. The project, which commenced June 11, 2026 and concludes May 31, 2029, will deliver high-throughput chemical transcriptomic profiling screening against 3,792 small molecules to...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $687,291 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award funds fundamental research to elucidate molecular mechanisms by which cancer driver mutations suppress antitumor immune responses, specifically focusing on the role of MLL3 (KMT2C) mutations in promoting regulatory T cell (Treg)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Herbert Irving Comprehensive Cancer Center (HICCC) a $193,926 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. This award supports the development and implementation of investigator-led clinical trials within the NCI Clinical Trials Network (NCTN), Experimental Therapeutics Clinical Trials Network (ETCTN), and NCI Community...
- Federal Project Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a Project Grant of $151,263 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, with completion targeted for August 31, 2027. This award supports research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The institutional award provides funding to develop research...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...